Geron has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Who owns Geron?
General Public Ownership The general public collectively holds 54% of Geron shares. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.
When was Geron founded?
1990, Delaware, United States
Geron Corporation/Founded
Geron, founded in 1992, was one of the first public companies to study embryonic stem cells. In the late 1990s its attention turned to telomerase, a compound the group identified through its study of stem cells as key to the aging process.
What does GERN company do?
Description. Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies.
Is TXMD a good buy?
The low price target for TXMD is $4.00, while the high price target is $9.00. TXMD analyst rating is Strong Buy.
What does Geron mean?
Geron as a boy’s name is of Irish and Gaelic origin meaning “gelding”.
What is a Geron?
Geron, an elder (from the Greek “γέρων”) of an Orthodox monastery (starets in Russian)
Is Phun a good buy?
Out of 2 analysts, 1 (50%) are recommending PHUN as a Strong Buy, 1 (50%) are recommending PHUN as a Buy, 0 (0%) are recommending PHUN as a Hold, 0 (0%) are recommending PHUN as a Sell, and 0 (0%) are recommending PHUN as a Strong Sell. What is PHUN’s earnings growth forecast for 2021-2023?
Will Rigl stock go up?
Rigel Pharmaceuticals Inc (NASDAQ:RIGL) The 6 analysts offering 12-month price forecasts for Rigel Pharmaceuticals Inc have a median target of 8.00, with a high estimate of 11.00 and a low estimate of 7.00. The median estimate represents a +106.19% increase from the last price of 3.88.
What kind of company is Geron Corporation ( Gern )?
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies, today reported financial results for the first quarter ended March 31, 2021, as well as company highlights and upcoming events.
When did Geron give out the stock options?
Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as inducements to three newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on October 16,…
When does the first quarter of 2021 start for Geron?
Welcome to this conference call to discuss Geron’s first-quarter 2021 financial results and recent company events. Geron (GERN) delivered earnings and revenue surprises of -12.50% and 82.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
When did Geron pull out of Imetelstat partnership?
Geron’s stock price plummeted when the company’s development partner, Janssen Biotech, pulled out of the imetelstat partnership on September 27, 2018, wiping out hundreds of millions of dollars of shareholder value. To learn more about this investigation and your rights, visit:
